OutSee Funding News-England- Based OutSee Secures £1.8Million Funding

OutSee is a genomics and drug discovery startup using a unique AI-based approach to predict disease and identify drug targets. Its proprietary technology, Nomaly, can predict disease traits directly from a single genome.

Unlike traditional methods that rely on known genetic patterns, Nomaly uses hypothesis-free predictive modelling based on core molecular and cellular biology.

Read Also - Swedish Fintech Startup Ankor Secures $1.3Million In Pre-Seed Round

This “genomics-first” method allows OutSee to uncover the hidden biological mechanisms behind diseases and works well alongside existing discovery pipelines.

Dr Julian Gough, CEO and Founder of OutSee, commented: OutSee’s Nomaly technology is a truly next-generation genomic analysis tool with the potential to transform drug discovery using powerful data-driven insights. It allows us to interrogate smaller datasets, and even data that has already been analysed, to uncover unique target insights that until now would have remained undetected. I would like to thank our investors, whose support in this endeavour will be crucial in allowing us to build out our in-house target identification program and establish new collaborative partnerships, and to our team for their continued hard work and dedication.

Nomaly can work effectively with small datasets and can also extract new, actionable insights from previously analysed data, supporting progress in therapeutic discovery and development. The technology is designed for broad application across various fields, with OutSee’s in-house program initially targeting CNS disorders, rare diseases, and metabolic conditions.

Dr Paul Wallace, Chair, OutSee, said: I would like to thank our investors and partners for their support and for their confidence in our mission to drive therapeutic discovery through our pioneering, genetics-first predictive genomics approach. This funding will enable us to leverage the full potential of Nomaly to uncover new therapeutic targets and bolster our in-house pipeline. We remain open to additional investment opportunities, and welcome enquiries from interested pharma and biotech industry partners.

The funding round was led by Ahren Innovation Capital, with additional support from Kadmos Capital, Empirical Ventures, and Panacea Ventures.

Dr Johnathan Matlock, Co-Founder and General Partner, Empirical Ventures, said: At Empirical Ventures, we’re seeking out companies that push beyond the boundaries of conventional methods in their fields to significantly enhance the real-world impact of these industries. It’s for this reason that we are delighted to be supporting the team at Outsee as it advances a solution that will unlock the future of target ID for drug discovery. The entrepreneurial drive and deep expertise of the team under Julian’s leadership, position Outsee at the forefront of this important progress in the drug discovery industry with its work capable of redefining the treatment of patients suffering from devastating diseases.

Dr. Joanna Green Principal at Ahren Innovation Capital shared her strong belief in OutSee’s approach noting that its genomics-first method provides capabilities that go well beyond existing technologies. She commented:

Nomaly has great potential to unlock a deeper understanding of genomic data, discover new therapeutic targets and drive the development of next-generation treatments for the entire spectrum of human disease. I look forward to seeing OutSee’s continued growth and success, and to working closely with Julian and the team to support them through this journey.

The funding will support OutSee’s next stage of growth by expanding its internal target discovery programs and building strategic partnerships with top pharmaceutical and biotech companies.

About OutSee

Founded in 2023, OutSee is focused on creating and applying advanced computational methods in genomics to drive drug target discovery and support precision medicine.